Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
254 - I'm curious as to why the STI Innovicares program is allowed to advertise specific brand name drugs on a website without PAAB review; especially given two main pharmaceutical companies are behind a large promotion of their brands (AZ/Sanofi)? Isn't this considered DTC advertising linked to brand name drugs? The website is at www.innovicares.ca and also has DTC ads and posters in addition to the website.
-
I have not reviewed the site as this is a forum for Q&A on the general meaning and application of the PAAB Code of Advertising Acceptance and not for advertising monitoring, reviews, or complaints. You may call me if you have questions about whether specific content on publicly accessible portions of the site exceed this restriction. As a general point, promotion of Rx drugs to consumers is permitted, but it is restricted to name, price, and quantity. You may call me if you have questions about whether specific content on publicly accessible portions of the site exceed this restriction. Note that Health Canada adjudicates complaints about DTC advertising of healthcare products.
